Why the study?
The real-world impact of switching to hs-cTn assays with sex-specific reference rates on patient outcomes and health service costs was poorly understood.
Does switching to high-sensitivity cardiac troponin assays reduce costs and MACE in patients presenting to the ED with suspected ACS?
Population
179,681 consecutive patients aged 20 and above presenting to 9 Australian EDs with suspected ACS
Comparison
Hospitals switching to hs-cTn assays vs hospitals continuing conventional assays
Design
Difference-in-differences analysis using linked administrative data from 9 tertiary hospitals
Follow-up
12 months
Authors
Loading...
May not yet warrant practice change in EDs; leaves open randomized tests of hs-cTn cost-effectiveness.
Does switching to high-sensitivity cardiac troponin assays reduce costs and MACE in patients presenting to the ED with suspected ACS?
Transitioning to high-sensitivity troponin assays for suspected ACS in the ED is highly cost-effective and associated with reduced 12-month MACE, particularly in women.
Pincombe et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: